Phage therapy is a treatment method that uses bacteriophages, a special virus, to treat various infections caused by bacteria. Phage therapy has shown great potential in treating drug-resistant bacterial infections, but further research and improvement are still needed to overcome existing challenges.

Overview of Market Development

The global phage therapy market is in a rapid development stage with broad prospects. With the intensification of antibiotic resistance, bacteriophage therapy as a new type of antibacterial method has received widespread attention, and the market size continues to expand. Multiple companies have made breakthroughs in this field, and bacteriophage products are gradually entering clinical trials and commercialization stages.

According to our research datas, the estimated revenue of the global phage therapy market in 2024 is $208 million, an increase of 9.04% compared to 2023. In the future, with the continuous breakthrough of scientific research and technology, bacteriophage therapy is expected to play a role in the treatment of more infectious diseases, and its market is expected to continue to expand. It is expected that by 2029, the global phage therapy market revenue will increase to $376 million. The CAGR for 2024-2029 is estimated to be 12.57%.

Segmented Market Analysis

In terms of types, bacteriophage therapy can be subdivided into DsDNA phage therapy, SsDNA phage therapy, and SsRNA phage therapy based on different types of bacteriophages. Among them, DsDNA phage therapy dominates the market, with an expected market share of 87.32% by 2024.

From the perspective of downstream applications, phage therapy is mainly used in fields such as animal health, human health, agriculture, and the food industry. Among them, the animal health field is its largest downstream application market, with an estimated application share of 42.74% in 2024.

Source: www.globalmarketmonitor.com

Market Analysis of Major Regions

From a regional perspective, the global phage therapy market is dominated by two major regions, North America and Europe. The revenue share of the phage therapy market in these two regions is about 80% of the global total revenue. Among all regions, North America is the largest revenue market. The data shows that the estimated revenue of the North American phage therapy market in 2024 is $99.71 million, and the revenue share is expected to reach 47.92%.

Regions	Market Revenue (Million USD)	Revenue Share
North America	99.71	47.92%
Europe	67.45	32.42%
Asia Pacific	30.26	14.54%
South America	7.89	3.79%
Middle East & Africa	2.78	1.34%